StrataCTX® As a Steroid Sparing Device

Description

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

Conditions

CTCL

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose is to determine if StrataCTX® can be used as a steroid sparing agent for the treatment of cutaneous reactions related to, cutaneous T Cell lymphoma (CTCL) and chemotherapy/immunotherapy treatments than the current standard treatment - topical steroids - in people who are receiving treatment for CTCL, or chemotherapy/immunotherapy for solid/hematologic malignancies. Subjects will have CTCL and are being treated with topical steroids, or being treated with chemotherapy/immunotherapy for another condition and have had cutaneous reactions that have warranted initiation of topical steroids.

Post-marketing Surveillance of StrataCTX® Flexible Wound Dressing for Use As a Steroid Sparing Agent

StrataCTX® As a Steroid Sparing Device

Condition
CTCL
Intervention / Treatment

-

Contacts and Locations

New York

Columbia University Irving Medical Center, New York, New York, United States, 10032

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥ 18 years
  • * Ability to sign informed consent document
  • * Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel
  • * Patients with a diagnosis of CTCL who have intractable pruritis
  • * Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief
  • * Patients on chemo/immunotherapy with drug induced rash
  • * Patients currently undergoing radiotherapy
  • * Patients currently receiving oral steroids
  • * Patients who are unable to apply topical medications

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Columbia University,

Larisa J. Geskin, MD, PRINCIPAL_INVESTIGATOR, Columbia University

Study Record Dates

2026-08